financetom
Business
financetom
/
Business
/
Update: Clearwater Analytics Shares Surge After Improved Q3 Results, Full-Year Revenue Outlook Increase
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Update: Clearwater Analytics Shares Surge After Improved Q3 Results, Full-Year Revenue Outlook Increase
Nov 9, 2024 12:27 PM

12:51 PM EST, 11/07/2024 (MT Newswires) -- (Updates with share price movement in the headline and first paragraph.)

Clearwater Analytics Holdings ( CWAN ) shares were up over 21% in recent trading on Thursday, a day after it reported Q3 results that improved year-over-year and raised its full-year revenue guidance.

The company reported Q3 non-GAAP earnings Wednesday of $0.12 per diluted share, up from $0.09 a year earlier.

Analysts polled by Capital IQ expected $0.11.

Revenue for the quarter ended Sept. 30 was $115.8 million, compared with $94.7 million a year earlier.

Analysts polled by Capital IQ expected $113.4 million.

The company said it expects Q4 revenue of $120.2 million. Analysts polled by Capital IQ expect $120.4 million.

For the full year, Clearwater Analytics ( CWAN ) said it now expects $445.5 million in revenue, compared with its previous estimate of $442 million to $444 million. Analysts polled by Capital IQ expect $445.9 million.

Price: 34.60, Change: +6.02, Percent Change: +21.06

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Theravance Biopharma marginally beats Q3 revenue estimates, YUPELRI sales up 15%
Theravance Biopharma marginally beats Q3 revenue estimates, YUPELRI sales up 15%
Nov 10, 2025
Overview * Theravance Q3 revenue slightly beats estimates, driven by Viatris collaboration * Adjusted net income for Q3 beats estimates, reflecting financial discipline * YUPELRI net sales in Q3 reach $71.4 mln, up 15% YoY Outlook * Theravance expects topline Phase 3 CYPRESS results in Q1 2026 * Company on track to achieve $50 mln TRELEGY sales milestone in 2025...
StandardAero Q3 Earnings, Revenue Rise
StandardAero Q3 Earnings, Revenue Rise
Nov 10, 2025
04:33 PM EST, 11/10/2025 (MT Newswires) -- StandardAero ( SARO ) reported Q3 earnings late Monday of $0.20 per diluted share, up from $0.06 a year earlier. Analysts polled by FactSet expected $0.20. Revenue in the three months ended Sept. 30 rose to $1.5 billion from $1.24 billion a year earlier. Analysts surveyed by FactSet expected $1.42 billion. The company...
TeraWulf Q3 Loss Widens, Revenue Rises
TeraWulf Q3 Loss Widens, Revenue Rises
Nov 10, 2025
04:33 PM EST, 11/10/2025 (MT Newswires) -- TeraWulf ( WULF ) reported a Q3 loss late Monday of $1.13 per diluted share, widening from a loss of $0.06 a year earlier. Analysts surveyed by FactSet expected a loss of $0.04. Revenue for the three months ended Sept. 30 was $50.6 million, up from $27.1 million a year earlier. Analysts polled...
Cell therapy firm ProKidney's Q3 net loss narrows 
Cell therapy firm ProKidney's Q3 net loss narrows 
Nov 10, 2025
Overview * ProKidney ended Q3 2025 with $272 mln in cash, supporting operations into mid-2027 Outlook * Company expects cash to support operations into mid-2027 Result Drivers * R&D EXPENSES - Decrease in R&D expenses due to winding down of completed or terminated trials Key Details Metric Beat/Mis Actual Consensu s s Estimate Q3 $38.76 Operatin mln g Expenses Q3...
Copyright 2023-2026 - www.financetom.com All Rights Reserved